Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Radiation: Applications

Radiation: Applications

The average temperature of Earth is the subject of much current discussion. Earth is in radiative contact with both the Sun and dark space; it receives almost all its energy from the radiation of the Sun and reflects some of it into outer space. Dark space is very cold, about 3 K, so Earth radiates energy into it. For instance, heat transfer occurs from soil and grasses, the rate of which can be so rapid that frost can occur on clear summer evenings, even in warm latitudes.
The average...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026

Same author

Salvage brachytherapy for locally recurrent prostate cancer after definitive radiotherapy - a multicentric French cohort by the SFRO brachytherapy group.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

Same author

Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation.

Clinical and translational radiation oncology·2024

Same author

[Does radiation therapy for prostate cancer increase the risk of second cancers?]

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024

Same author

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

ESMO open·2024

Same author

Transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma: Long-term results of RTF3 regimen.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023

Search research articles

Related Experiment Video

Updated: May 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

[Hypofractionation and radiotherapy: "the eternal return"].

J-M Cosset¹, F Mornex, F Eschwège

¹Département d'oncologie/radiothérapie, institut Curie, 75005 Paris, France; Service de radiothérapie, hôpital privé des Peupliers, groupe générale de santé, 75013 Paris, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique

|August 24, 2013

Summary

This summary is machine-generated.

Hypofractionation, using fewer high-dose radiation fractions, has a complex history. While promising for prostate cancer, caution is advised due to uncertainties in radiobiological models and potential late toxicity.

Keywords:

Cancer de prostate Facteurs temps Fractionation Fractionnement Prostate cancer Radiotherapy Radiothérapie Time factors

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Characterization of Recombination Effects in a Liquid Ionization Chamber Used for the Dosimetry of a Radiosurgical Accelerator

Characterization of Recombination Effects in a Liquid Ionization Chamber Used for the Dosimetry of a Radiosurgical Accelerator

Published on: May 9, 2014

Related Experiment Videos

Last Updated: May 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Characterization of Recombination Effects in a Liquid Ionization Chamber Used for the Dosimetry of a Radiosurgical Accelerator

Characterization of Recombination Effects in a Liquid Ionization Chamber Used for the Dosimetry of a Radiosurgical Accelerator

Published on: May 9, 2014

Area of Science:

Radiotherapy
Radiation Oncology
Radiobiology

Background:

Hypofractionation, the use of fewer, higher-dose radiation fractions, has historical roots in radiotherapy but has faced challenges due to evolving radiobiological understanding.
Past approaches like the Nominal Single Dose (NSD) model led to underestimations of late toxicity, increasing complications in patients.
The linear-quadratic (LQ) model improved understanding of fractionation sensitivity but has limitations at low and high doses per fraction.

Observation:

Prostate cancer fractionation sensitivity is debated, with some studies suggesting a low alpha/beta ratio.
The precise alpha/beta ratio for prostate cancer remains unevaluated, with proposed values ranging from very low (1.5 Gy) to low (3-4 Gy).
Current data are insufficient to definitively determine the optimal hypofractionation strategy for prostate cancer.

Findings:

Historical attempts at hypofractionation, such as those using the NSD model, resulted in significant late toxicity.
The LQ model provides a better framework for understanding radiation fractionation but requires careful application, especially concerning its limitations.
The alpha/beta ratio in prostate cancer is a critical parameter for hypofractionation, but its exact value is still under investigation.

Implications:

Further research is needed to precisely determine the alpha/beta ratio for prostate cancer to optimize hypofractionation protocols.
Clinicians should exercise caution when implementing hypofractionation for prostate cancer, considering the potential for increased late toxicity.
Careful dose adjustments are necessary when reducing the total number of fractions to mitigate risks associated with hypofractionation.